Kornimate/medical-research-clean huggingface dataset:
novel meal service improves nutritional intake

Conditions: Malnutrition

Summary: this study aims to investigate whether a novel meal service foodforcare (ffc), comprising 6-protein-rich meals a day following proactive advice from a nutritional assistant, improves dietary intake and patient satisfaction, compared to the traditional 3-meals a day service (tms).

the investigators performed a quasi experimental study at medical (gastroenterology) and surgical (gynecology, urology, orthopedics) wards. patients were offered tms (july 2015 - may 2016; n=326) or ffc meal service (after stepwise introduction per ward from january 2016 - december 2016; n=311). primary outcome was the mean percentage of protein and energy intake relative to requirements, between patients receiving tms and those receiving ffc, on the first and fourth day of full oral intake. patient satisfaction comprised rating of the experienced quality of the food and the meal service and by means of a validated questionnaire.

Eligibility criteria:
inclusion criteria: * dutch speaking * aged 18 years or older * exclusively oral intake * expected hospital stay of at least 1 day exclusion criteria: * patients with tube- or parenteral feeding * a language barrier * considered to be too weak to adequately answer our questions

Keywords: meal service protein intake satisfaction hospitalized patients
novel device for reducing catheter-related infections

Conditions: Intensive Care

Summary: this study is a pilot study of the safety, tolerability and efficacy of an investigational central venous catheter device used in conjunction with a standard central venous catheter. the hypothesis is that utilization of a catheter device incorporating cyanoacrylate will reduce catheter colonization by bacteria, and may decrease the rate of catheter-related bloodstream infections.


Eligibility criteria:
inclusion criteria: * admission in the icu at time of catheter insertion * indication for central venous catheter placement * de novo catheter insertion in the subclavian or internal jugular veins exclusion criteria: * anticipated catheter duration \< 72 hours * planned guidewire exchange * documented bacteremia within 48 hours prior to catheter placement * extensive skin breakdown near the site of potential catheter placement * emergent line placement * screening labs with anc \< 500 or platelets \< 50k * hypersensitivity to cyanoacrylates or formaldehyde * prior enrollment in study
exploring the effect of footbaths on increasing the success rates in vitro fertilization

Conditions: Infertility; In Vitro Fertilization

Summary: to evaluate the effectiveness of warm-water footbaths in enhancing pregnancy rates during ivf and to explore the underlying mechanisms involved.

additionally, this research will assess whether a complementary and alternative medicine (cam) approach utilizing warm-water footbaths is effective in improving pregnancy rates for women undergoing ivf. furthermore, the potential mechanisms by which footbaths may enhance ivf success rates will be elucidated. the specific aims of this research proposal are as follows: 1. to explore the correlation between health statuses, sleep quality, stress, and infertility incidence. 2. to investigate the association between health statuses, sleep quality, stress, and multiple inflammatory indexes in infertile women, including: 2-1. systemic immune inflammation index (sii) 2-2. lymphocyte count (lc) 2-3. platelet and neutrophil count product (ppn) 2-4. platelet-lymphocyte ratio (plr) 2-5. neutrophil-lymphocyte ratio (nlr) 2-6. lymphocyte-monocyte ratio (lmr) 3. the effects of footbaths on stress and sleep: to examine the effects of footbaths on reducing stress and improving sleep quality, which may enhance pregnancy success rates during ivf treatment in infertile women. 4. the impact on inflammatory markers: to investigate whether footbaths can reduce levels of inflammatory markers and inflammatory cytokines during ivf treatment, potentially enhancing pregnancy success rates in infertile women.

Eligibility criteria:
inclusion criteria: * women aged 18\~45 years * diagnosed with male factor infertility * tubal factor infertility, or unexplained infertility, and undergoing an ivf treatment. exclusion criteria: * participants having adenomyosis, severe endometriosis * a history of more than two ivf treatments * any comorbidity or uncontrolled systemic diseases such as hypertension, diabetes, chronic heart disease or chronic renal disease that can affect the treatment process.

Keywords: infertility in vitro fertilization stress sleep quality inflammation footbath
aripiprazole and prolactin study

Conditions: Hyperprolactinemia

Summary: antipsychotic medicines are used routinely in people with severe mental illness or learning disability. antipsychotics often induce hyperprolactinemia (high prolactin level) and in almost all women, and some men, this causes hypogonadism (impaired ovarian or testicular function)often with osteoporosis, partly explaining psychiatric patients' high fracture risk. reducing prolactin by changing antipsychotic or adding a dopamine agonist often worsens psychosis. adding aripiprazole to current antipsychotic normalizes prolactin in adult schizophrenic patients, without serious side effects. we thus plan a study of add-on aripiprazole in people with antipsychotic induced hyperprolactinemia. our main hypothesis is that aripiprazole will normalize or reduce prolactin sufficiently to restore normal ovarian and testicular function. our secondary hypothesis is that restoration of normal ovarian and testicular function will improve bone mineral density in patients in whom this was reduced at the time of entry into the study.


Eligibility criteria:
inclusion criteria: * participants willing and able to give informed consent for participation in the study. * males or females, aged 16-50 years (women), 16-60 (men). * diagnosed with antipsychotic induced hyperprolactinaemia of sufficient severity to induce secondary hypogonadism. * stable dose of current regular antipsychotic medication for at least three months prior to study entry. * female participants of child bearing potential willing to ensure that they or their partner use effective contraception during the study and for 1 month thereafter * able (in the investigators opinion) and willing to comply with all study requirements. * willing to allow his or her general practitioner and consultant to be notified of participation in the study. exclusion criteria: * pregnancy or breastfeeding * any significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. * plans to donate blood during the study * participants who have participated in another research study involving an investigational product in the past 8 weeks * any significant disease or disorder which, in the opinion of the investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study. * plans to donate blood during the study * participants who have participated in another research study involving an investigational product in the past 8 weeks

Keywords: antipsychotic hyperprolactinemia hypogonadism aripiprazole
population-based investigation of aneurysm incidence

Conditions: Intracranial Aneurysm

Summary: most intracranial aneurysms are found accidentally in neurovascular imaging. and these inspection methods are limited by the problems of instrument fixation, radiation, time-consuming, contrast agent toxicity and so on. at present, blood test is an ideal alternative method for early diagnosis. compared with imaging examination, it is economical, general screening and convenient. blood test is simple to operate, easy to be accepted by patients, and less invasive. early screening of aneurysms can be performed.


Eligibility criteria:
inclusion criteria: * age 35-75 * individuals with normal cognitive and communication abilities * no serious complications, such as uncontrolled hypertension, diabetes or other chronic diseases that may affect the test results. * basic blood test is normal or close to normal range. exclusion criteria: * pregnancy * severe heart disease, renal insufficiency, liver dysfunction and other major diseases. * in the past 6 months, there were strokes, or other types of intracranial tumors, infections and other diseases that may affect the screening results. * there are metal implants, including dentures, pacemakers, etc. * using or recently used drugs that may affect blood biomarkers ( such as anticoagulant drugs, immunosuppressive agents, etc. ). * there are serious mental illness or cognitive dysfunction, such as claustrophobia, unable to cooperate with the completion of the test. * it is currently participating in other clinical trials or has participated in other clinical trials in the past 3 months.

Keywords: intracranial aneurysms screening blood test
vaccine therapy in treating patients with malignant melanoma

Conditions: Melanoma (Skin)

Summary: rationale: vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. purpose: this phase ii trial is studying vaccine therapy to see how well it works in treating patients with malignant melanoma.

objectives: * determine the response in patients with in-transit cutaneous malignant melanoma treated with active immunotherapy comprising polyvalent melanoma vaccine (canvaxin™). outline: this is an open-label, multicenter study. patients receive polyvalent melanoma vaccine (canvaxin™) subcutaneously to the armpit and groin areas every 2 weeks for approximately 10 weeks (5 doses) and then every 4 weeks for up to approximately 1 year of total treatment (total of 15 doses). patients with no evidence of response at week 24 receive no further treatment. patients whose disease continues to respond after completion of study treatment are eligible for a new study in which they will continue treatment with polyvalent melanoma vaccine (canvaxin™). after completion of study treatment, patients are followed at 30 days. projected accrual: a total of 100 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically confirmed malignant melanoma * at least 1 in-transit skin lesion measuring 3-10 mm in the longest diameter patient characteristics: age * 18 to 80 performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * not specified radiotherapy * not specified surgery * not specified

Keywords: stage iii melanoma
association between asthma and food allergy

Conditions: Food Allergy Suspected; Food Allergy Proved

Summary: prevalences of food allergies and asthma increased in the population during the last decades. these two pathologies, responsible for a real burden, are often associated and are to be considered as comorbidities; this aspect is more and more studied in the literature and many authors tried to find a link between diets and asthma. the narrow link between these two atopic pathologies and the fact that food allergy can come along with respiratory symptoms also in patients without history of asthma must be better understood, considered into the management of food allergy. the main objective of this study is to study the prevalence of signs and/or symptoms suggestive of bronchial hyperreactivity, during an oral food challenge (ofc) in patients older than 5 years. the secondary objective is to study the risk factors to develop asthma during a food allergy reaction. this historical-prospective single center study , was realized in the allergy unit of the university hospital of montpellier. all the patients having been hospitalized for a positive ofc between january, 2001 and january, 2016 were included. the diagnosis of asthma was established according to the recommended international clinical and physiological criteria. prevalence of bronchial hyperreactivity during ofc among those with positive ofc, was calculated. the search for risk factors was made by a logistic regression univariate then multivariate, completed by a decision tree.


Eligibility criteria:
inclusion criteria: * patient hospitalized for oral food challenge at the hospital exclusion criteria: * patient want to leave the protocol * patient take medication forbidden during the study

Keywords: food allergy asthma predictive factor exacerbation prevalence
hyperbaric oxygen and fibromyalgia: randomised prospective clinical trial

Conditions: Fibromyalgia

Summary: the aim of the study is to evaluate the effect of hyperbaric oxygen therapy (hbot) on patients suffering from chronic pain syndrome (fibromyalgia).

the study is a prospective, randomized, cross-over trial. patients will be randomized into two groups (test and control) to receive the hbot at the beginning of the trial or 2 months afterwards. the control group will receive its treatment after the elapsed two months. this study will be a prospective, randomized cross over study. after signing a written informed consent, all patients will be invited to a 2 hour examination, including pain sensitivity examination and a series of questionnaires. in addition, prior to the beginning of the treatment all patients will have chest x-ray, neurological examination, cognitive evaluation and brain metabolism evaluation (spect scan). a similar evaluation will be done after the 8 weeks, test versus control time period, and another evaluation will be held after 16 weeks. the hbot procedure will be performed in the hyperbaric chamber at assaf harofeh medical center, israel. the following hbot protocol will be applied for the treated group: 8-week, 5 times a week administration of 100% o2 for 90 minutes at a pressure of 2 ata. after 8 weeks the control group, that did not received hbot, will receive the same hbot protocols. at baseline, after 2 months and after 4 months all patients will undergo complete neurologic and pain evaluation and brain spect scan (total of 3 evaluation and scan per patient).

Eligibility criteria:
inclusion criteria: * fibromyalgia diagnosed by physical examination of pain sensitivity, by dolorimeter and finger pressure. exclusion criteria: * any past hyperbaric oxygen therapy * chest x-ray pathology which does not allow the income into the hyperbaric chamber. * middle ear problems. * patients, who cannot "pump", equals middle ear pressure, effectively. * patients who suffer from claustrophobia. * inability or refusing to sign the informed consent form

Keywords: hyperbaric oxygen fibromyalgia chronic pain syndrome
dendritic cell vaccine in treating patients with indolent b-cell lymphoma or multiple myeloma

Conditions: Lymphoma; Multiple Myeloma and Plasma Cell Neoplasm

Summary: rationale: biological therapies, such as a dendritic cell vaccine made with a patient's cancer cells, may stimulate the immune system in different ways and stop cancer cells from growing. purpose: this phase i/ii trial is studying the side effects of dendritic cell vaccine and to see how well it works in treating patients with indolent b-cell lymphoma or multiple myeloma.

objectives: * evaluation of feasibility of dendritic cell (dc)-based vaccination program using autologous tumor cells and/or lysates in patients with indolent b cell lymphomas or multiple myeloma as an adjuvant therapy to induce immune response in remission after cytoreductive treatment. * evaluation of the immune response of patients treated with this regimen. * evaluation the progression-free survival of patients treated this regimen. * evaluate the adverse events of this regimen in these patients. outline: patients receive intranodal (under ultrasound guidance) or subcutaneous vaccinations of adjuvant electrofusion hybrids of autologous dendritic cells (dc) with autologous lymphoma cells, electrofusion hybrids of allogeneic dc with autologous lymphoma cells, and/or autologous dc pulsed with autologous tumor lysate cells in weeks 0, 2, 4, 8, 12, 18, 26, and 50.

Eligibility criteria:
disease characteristics: * histologically confirmed diagnosis of 1 of the following: * mantle cell lymphoma * marginal zone lymphoma * follicular lymphoma * small lymphocytic lymphoma/chronic lymphocytic leukemia * multiple myeloma * lymphoplasmacytic lymphoma/waldenström macroglobulinemia * diffuse large b-cell lymphoma * adequate sample size and lymphoma cell content in the fresh tissue collected * no bulky or progressive disease patient characteristics: * life expectancy \> 3 months * no evidence of lung, heart, liver, or renal failure or severe neurologic disorder * no autoimmune disease or atopic allergy * no hiv positivity * no other malignancy prior concurrent therapy: * not specified

Keywords: dendritic cell vaccine tumor cell lysate lymphoma
efficacy of lentinula edodes-derived supplement (ahcc®) in promoting negativity of persistent hpv infection

Conditions: HPV Infection

Summary: this retrospective, multicenter clinical study evaluates the efficacy and safety of an ahcc®-based supplement derived from lentinula edodes in promoting the negativity of persistent hpv infection lasting more than six months. the study involves three groups: unvaccinated participants receiving ahcc®, vaccinated participants receiving both ahcc® and the hpv vaccine, and vaccinated participants receiving only the hpv vaccine.

the study investigates the ability of ahcc® (active hexose correlated compound) to support immune modulation and promote negativity of persistent hpv infections, which are associated with an increased risk of cervical cancer. participants are categorized into three groups based on vaccination and supplement use. outcomes include the proportion of participants achieving hpv negativity and the safety and tolerability of the supplement over a 4-6 month period. the study aims to evaluate the potential of ahcc® as a complementary approach for managing persistent hpv infection.

Eligibility criteria:
inclusion criteria: * female participants aged 18 years or older. * persistent hpv infection for at least 6 continuous months, confirmed by dna-hpv testing. * no prior treatment for cervical lesions via conization. * no prior hpv vaccination exclusion criteria: * current or planned pregnancy during the study period. * immunocompromised status, including known hiv infection. * severe or high-grade cervical lesions. * known allergy or hypersensitivity to ahcc® or vaccine components.
feasibility of an evidence-based walking program in cancer pts 60+ during chemotherapy

Conditions: Breast Cancer; Colon Cancer; Lung Cancer

Summary: the study will look at conducting a medium-intense walking program called walk with ease with cancer patients age 60 and above who are starting chemotherapy treatment. we will measure how many of these patients complete their participation in this program.

the primary purpose of this study is to evaluate the feasibility of implementing a moderate-intensity walking program (walk with ease/wwe) among cancer patients, age ≥60 years, as they undergo cytotoxic chemotherapy treatment. feasibility will be determined based on the rate of participation in the wwe program. as secondary objectives, we will also establish the rate of completion of a number of instruments, including a geriatric assessment tool, and other instruments that measure self-reported quality of life (e.g., fatigue, depression, and pain), and self-reported physical activity (pa). data from these instruments, as well as from serial measurements of a biomarker of aging (p16ink4a) will be explored and used to inform future studies designed to evaluate any relationship between these variables and participation in the wwe program. we propose a sample (n=30) of cancer patients ≥60 years of age with potentially curable cancer and a diagnosis of stage i-iii breast cancer, stage i-iii lung cancer, or stage ii-iii colon cancer, who are about to begin chemotherapy. participation will be defined as completing the 6-week wwe program. results from this study will be used in an ro1 application to the national cancer institute (nci) pertaining to pa interventions among cancer patients and the effects of biomarkers on prognosis and survival.

Eligibility criteria:
inclusion criteria: * ≥60 years of age, male or female * histologically confirmed stage i, ii or iii breast cancer (if the patient has had more than one breast cancer diagnosis, then the most recent diagnosis); stage i, ii or iii lung cancer, or stage ii or iii colon cancer * scheduled to begin a chemotherapy (or concomitant chemoradiotherapy) regimen that will last at least 6 weeks in duration * english speaking * irb approved, signed written informed consent * approval from their treating physician to engage in moderate-intensity physical activity * patient-assessed ability to walk and engage in moderate physical activity * willing and able to meet all study requirements. exclusion criteria: * one or more significant medical conditions that in the physician's judgment preclude participation in the walking intervention * cancer surgery scheduled within the study period * unable to walk or engage in moderate-intensity physical activity

Keywords: physical activity chemotherapy elderly geriatric walking geriatric assessment geriatric oncology
evaluation of brain plasticity in premature infants at school age after cognitive remediation

Conditions: Premature Childbirth

Summary: infantile brain plasticity is still a poorly known phenomenon. however, neuropsychological disorders and behavioral deficits are common disorders that can have serious consequences for school enrollment, family and social adjustment, as well as repercussions on future adult lives. in addition, generally very premature infants (tgp) have identifiable executive function disorders (ef), particularly those involving attentional processes such as working memory (wm). the main objective of the study is to evaluate the effects of cognitive remediation (cr) strategies on the brain plasticity of the cortical areas involved in the management of wm in school-aged tgp children (8 years). the secondary objective of the study is to evaluate the action of cr on the development of cortical areas concerned it is a monocentric, prospective and comparative study of the exposed type (to cognitive remediation) - unexposed. recruitment and data collection are carried out prospectively, in connection with the original study (epiremed). included patients will be explored by magnetic resonance imaging (mri) 3 resting state tesla. the main hypothesis is that cr strategies have a beneficial effect on the cognitive processing of visual-spatial executive functions, but also on the cortical areas involved in brain plasticity in general (indirect benefits); not to mention the psychological benefits ad hoc to such studies (self-esteem, increased concentration, new stress management strategies put in place). the ultimate objective of this study is to better understand the mechanisms of cerebral plasticity concerning higher executive functions. moreover, this study should make it possible to confirm the improvement of the overall fate of the child by better understanding the neuropsychological and anatomical origins of his disorders. interventions taking into account the environment of the very premature baby are necessary because it is closely linked to the developmental future.


Eligibility criteria:
inclusion criteria: * children born between 24 and 34 weeks of amenorrhea and living in the provence region * possessing an intelligence quotient (iq) greater than 70 exclusion criteria: * child not understanding french * child who did not have all the interventions in the epiremed study